Pharmafile Logo
Pharmafocus logo
Advanced Search

Herceptin

Showing 15 posts of 53 posts found.

fda2outsideweb

FDA unanimously recommends Mylan and Biocon’s Herceptin biosimilar

July 14, 2017
Manufacturing and Production, Medical Communications, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, healthcare, life sciences, pharma, pharmaceuticals

Mylan and Biocon have revealed that their biosimilar version of Roche and Genentech’s Herceptin (trastuzumab) has received unanimous recommendation from …

News
mylan

Mylan’s pathway to launch of biosimilar to Herceptin cleared by Roche

March 13, 2017
Manufacturing and Production, Sales and Marketing Genentech, Herceptin, Mylan, Roche, biosimilar

Mylan scored a big victory in its plan to launch its biosimilar to Roche’s blockbuster, Herceptin, after Roche and itself …

News
images

Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results

March 2, 2017
Research and Development Herceptin, Perjeta, Roche

Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. …

News
lab

EMA accepts regulatory submission for proposed Herceptin biosimilar

August 26, 2016
Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab

Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …

News
clinical_trial_4

Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan

July 22, 2016
Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab

Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …

News

Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial

June 6, 2016
Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab

Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

Two-drug combo shown to significantly shrink breast cancer in days

March 10, 2016
Medical Communications, Research and Development GSK, Herceptin, Novartis, Roche, Tyverb

Results of a clinical trial have revealed that Novartis’ Tyverb (lapatinib), in combination with Roche’s Herceptin (trastuzumab), can significantly shrink …

News
roche_glass_building

Roche beats estimates with strong 2015 sales

January 28, 2016
Medical Communications, Sales and Marketing Esbriet, Herceptin, Roche, avastin

Roche reported full-year financial results today, beating analysts’ estimates, with the Swiss drugmaker announcing Group sales increases for 2015 in …

News
Herceptin image

Breast cancer treatment market booming

March 19, 2015
Research and Development, Sales and Marketing Frost, Herceptin, Kadcyla, Roche, breast cancer, oncology, targeted, tykerb

The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …

News
Herceptin

Herceptin faces UK competition within months

April 11, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biocon, Herceptin, Hospira, Perjeta, breast cancer

Roche’s blockbuster breast cancer drug Herceptin may soon be under threat from copycat treatments after a court in the UK …

News
Biocon image

Novartis sues Biocon

April 4, 2014
Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir

India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …

News
herceptin_roche_cancer

India court grants Herceptin injunction

February 10, 2014
Research and Development, Sales and Marketing Biocon, Herceptin, India, Mylan, Roche

Roche has been granted an injunction by a court in India to prevent generic manufacturers of its ageing breast cancer …

News
Biocon image

Herceptin biosimilar set for Indian market

January 21, 2014
Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab

Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …

News
Herceptin image

The new paradigm in oncology drug marketing

October 21, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Herceptin, Roche, marketing, oncology

Twenty years ago drugs to treat cancer were made up of chemotherapy agents which are essentially ‘blunt tools’ against the …

Feature
Roche image

Roche rules out merger talk

October 18, 2013
Sales and Marketing Cancer, Herceptin, Novartis, Roche, merger

Roche has dismissed talk of merging with fellow Swiss manufacturer Novartis as it revealed its results for the last three …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025